CN109942597B - 一类芳基异喹啉并噁唑季铵盐类化合物、其制备方法及用途 - Google Patents
一类芳基异喹啉并噁唑季铵盐类化合物、其制备方法及用途 Download PDFInfo
- Publication number
- CN109942597B CN109942597B CN201711384769.8A CN201711384769A CN109942597B CN 109942597 B CN109942597 B CN 109942597B CN 201711384769 A CN201711384769 A CN 201711384769A CN 109942597 B CN109942597 B CN 109942597B
- Authority
- CN
- China
- Prior art keywords
- cancer
- compound
- quaternary ammonium
- ammonium salt
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- -1 Aryl isoquinoline oxazole quaternary ammonium salt compounds Chemical class 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title abstract description 32
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 21
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 19
- 208000034578 Multiple myelomas Diseases 0.000 claims abstract description 17
- 206010025323 Lymphomas Diseases 0.000 claims abstract description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 6
- 201000005202 lung cancer Diseases 0.000 claims abstract description 6
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 6
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 5
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 5
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 5
- 201000007270 liver cancer Diseases 0.000 claims abstract description 5
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 74
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 229940072107 ascorbate Drugs 0.000 claims description 2
- 229940077388 benzenesulfonate Drugs 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 claims description 2
- 125000005879 dioxolanyl group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 229960001860 salicylate Drugs 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 229940022663 acetate Drugs 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940001468 citrate Drugs 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 150000005838 radical anions Chemical class 0.000 claims 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 25
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- 230000000259 anti-tumor effect Effects 0.000 abstract description 5
- 238000000338 in vitro Methods 0.000 abstract description 4
- 208000029742 colonic neoplasm Diseases 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 35
- 238000005160 1H NMR spectroscopy Methods 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 9
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 9
- 229940093265 berberine Drugs 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000012258 culturing Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 229930014626 natural product Natural products 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical group C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 3
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000000690 anti-lymphoma Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- ZEVCHJDMHBSFEV-UHFFFAOYSA-N 12-(2-bromopyridin-3-yl)dodecyl 2-methylprop-2-enoate Chemical compound C(C(=C)C)(=O)OCCCCCCCCCCCCC=1C(=NC=CC=1)Br ZEVCHJDMHBSFEV-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 102100028226 COUP transcription factor 2 Human genes 0.000 description 2
- 101710188750 COUP transcription factor 2 Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 229940124660 anti-multiple myeloma Drugs 0.000 description 2
- 150000003836 berberines Chemical class 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 238000006021 Dakin-West synthesis reaction Methods 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- PPERNQCQZGXRNO-UHFFFAOYSA-N O1C(NC=C1)=O.N1=CC=CC=C1 Chemical class O1C(NC=C1)=O.N1=CC=CC=C1 PPERNQCQZGXRNO-UHFFFAOYSA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- BFPLMTPHDFFMTG-UHFFFAOYSA-N [1,3]oxazolo[5,4-b]pyridine Chemical class C1=CN=C2OC=NC2=C1 BFPLMTPHDFFMTG-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002634 anti-blastic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940006460 bromide ion Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008394 flocculating agent Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229940006461 iodide ion Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229930013397 isoquinoline alkaloid Natural products 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- HNKLPNDFOVJIFG-UHFFFAOYSA-N oxalic acid;platinum Chemical compound [Pt].OC(=O)C(O)=O HNKLPNDFOVJIFG-UHFFFAOYSA-N 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及有机化学及药物化学领域,具体涉及一类如式1所示的芳基异喹啉并噁唑季铵盐类化合物、制备方法及其在制备用于治疗肿瘤或癌症的药物中的用途。本发明的芳基异喹啉并噁唑季铵盐类化合物具有较好的体外抑制多发性骨髓瘤、淋巴瘤细胞生长的作用,另外,该类化合物还对肺癌、结肠癌、乳腺癌、肝癌、前列腺癌细胞等具有一定的抑制活性,表明该类化合物具有广泛的抗肿瘤作用。
Description
技术领域
本发明涉及有机化学及药物化学领域,具体涉及芳基异喹啉并噁唑季铵盐类化合物、制备方法及其在制备用于治疗肿瘤或癌症的药物中的用途。
背景技术
季铵盐(四级铵盐)为铵离子中的四个氢原子都被烃基取代而生成的化合物。其中四个烃基可以相同,也可以不同;阴离子多是卤素负离子(F-、Cl-、Br-、I-),也可是酸根 (如HSO4 -、RCOO-等)。季铵盐类化合物在医药、化工等领域都有着极其广泛的应用,如用于杀菌剂、消毒剂、柔软抗静电剂、絮凝剂破乳剂、钻井液、粘弹性表面活性剂(VES) 压裂液、减阻剂、增稠剂、阴离子增效剂、相转移催化剂等。
该类化合物具有不同的生理活性,如甲基丙烯酰氧十二烷基溴吡啶 (12-methacryloyloxydodecylpyridinium bromide,MDPB)和氯化十六烷吡啶 (Cetylpyridiniumchloride,CPC)可以用于口腔消毒剂(Sreenivasan P1,Gaffar A. Antiplaque biocidesand bacterial resistance:a review.J Clin Periodontol.2002 Nov;29(11):965-74)。来自于海洋生物的3-烷基吡啶季铵盐多聚物具有抗肺癌活性(Zovko A1,Viktorsson K,Lewensohn R,K,M,Xing H,Kem WR,Paleari L,Turk T. APS8,a polymericalkylpyridinium salt blocksα7nAChR and induces apoptosis in non-small celllung carcinoma.MarDrugs.2013Jul 16;11(7):2574-94)。来源于传统中药活性成分的盐酸小檗碱,为芳基异喹啉类生物碱,分子结构中具有吡啶季铵盐片段,临床广泛用于治疗肠炎菌痢等。现代研究表明,小檗碱及其类似物还具有抗肿瘤、糖尿病、心血管病、中枢神经系统疾病等药理作用(Singh IP,Mahajan S.Berberine and its derivatives:a patentreview(2009-2012).Expert Opin TherPat.2013,23(2):215-231)。
噁唑并吡啶季铵盐类化合物鲜有文献报道,仅有的几篇文献以吡啶噁唑酮类化合物为主,该类化合物可作为合成中间体发生1,3-偶极环加成反应用以制备杂环化合物(Kazhkenov ZG1,Bush AA,Babaev EV.Dakin-West trick in the design of novel 2-alkyl(aralkyl)derivatives ofoxazolo[3,2-a]pyridines.Molecules.2005Sep 1;10(9):1109-18)。发明人在实验研究中发现,作为黄连素类似物的芳基异喹啉并噁唑季铵盐化合物具有较好的体外抑制多发性骨髓瘤、淋巴瘤细胞生长的作用,活性均优于天然产物黄连素,并且在动物体内显著抑制多发性骨髓瘤细胞生长,不影响动物体重,具有开发成药的潜力。另外,该类化合物还对肺癌、结肠癌、乳腺癌、肝癌、前列腺癌细胞等具有一定的抑制活性,说明该类化合物具有广泛的抗肿瘤作用。
发明内容
本发明一个目的是提供一种式1所示的芳基异喹啉并噁唑季铵盐类化合物。
本发明的另一个目的是提供一种包含治疗有效量的一种或多种式1所述的芳基异喹啉并噁唑季铵盐类化合物的药物组合物。
本发明的另一个目的是提供式1所述的芳基异喹啉并噁唑季铵盐类化合物的制备方法。
本发明的再一个目的是提供式1所述的芳基异喹啉并噁唑季铵盐类化合物在用于制备治疗肿瘤或癌症的药物中的用途。
本发明涉及一种如式1所示的芳基异喹啉并噁唑季铵盐类化合物:
其中,R11、R12、R13、R14、R15、R21、R22、R23、R24各自独立地选自氢、羟基、氨基、巯基、取代或未取代的C1-C6烷基、取代或未取代的C6-C12芳基、取代或未取代的C1-C6 烷氧基、C1-C6烷氨基、C1-C6烷硫基、C1-C6烷氧基甲酰基、C6-C12芳醚基、C6-C12 芳氨基、C6-C12芳硫基、硝基、C1-C6酰胺基或卤素;所述取代的取代基为羟基、氨基、巯基、卤素、C6-C12芳基或C1-C6烷基中的一个或多个;
或,R11、R12、R13、R14、R15中相邻的两个连接起来与相连的苯环上的碳原子形成一个5-7元环烷基或5-7元杂环基,其中,所述的5-7元杂环基包含选自O、S或N中1-3 个的杂原子;
Y-为酸根阴离子,选自无机酸根离子、有机酸根离子,包括但不限于硝酸根离子、硫酸根、磷酸根、硫酸氢根离子、磷酸二氢根离子、甲磺酸根离子、苯磺酸根离子、醋酸根离子、酒石酸根离子、枸橼酸根离子、马来酸根离子、琥珀酸根离子、柠檬酸根离子、水杨酸根离子、甘油酸根离子、抗坏血酸根离子、氟离子、氯离子、溴离子或碘离子。
优选地,
R11、R12、R13、R14、R15、R21、R22、R23、R24各自独立地选自氢、甲氧基、乙氧基、苄氧基、三氟甲氧基、羟基、羟基甲基、甲氧基甲酰基;或,
R11、R12、R13、R14、R15中相邻的两个连接起来与相连的苯环上的碳原子形成一个二氧五环基;进一步优选,R11、R12、R13、R14、R15中相邻的两个连接起来与相连的苯环上的碳原子形成一个1,3-二氧五环基;
Y-为醋酸根离子、硝酸根离子、氟离子、氯离子、溴离子或碘离子。
在本发明一个优选的实施方案中,所述的芳基异喹啉并噁唑季铵盐类化合物优选为:
在本发明中,“C1-C6烷基”是指具有1至6个碳原子的直链或支链烷基,非限制性地包括甲基、乙基、丙基、异丙基、正丁基、叔丁基等;在本发明中,“C1-6烷氧基”是指-O- (烷基)和-O-(未取代的环烷基),其中烷基的定义如上所述,非限制性实施例包含甲氧基、乙氧基、丙氧基、丁氧基、环丙氧基、环丁氧基、环戊氧基、环己氧基等。
在本发明中,“5-7元环烷”是指具有5至7个碳原子的环状烷基,非限制性地包括环戊基、环己基、环庚基等。
在本发明中,“5-7元杂环基”是指含有1-3个选自N、O、S的5-7元杂环基,非限制性地包括吡咯烷基、咪唑烷基、哌啶环基、哌嗪基、氮甲基哌嗪基、2-氧代哌啶基、2- 氧代哌嗪基、吗啉基、硫代吗啉基、2-氧代吗啉基、噁唑烷基、噻唑烷基、1,3-二氧五环基、氮杂环庚烷基等,优选为1,3-二氧五环基、吡咯烷基、哌啶基、哌嗪基、氮甲基哌嗪基、吗啉基。
在本发明中,“芳基”是指具有共轭的π电子体系的6至14元全碳单环或稠和多环(共享毗邻碳原子对的环),包含部分氢化的所述多环,如苯基、菲基、萘基、1H-吲哚和1,2,3,4- 四氢萘基等,所述芳基优选为苯基、1H-吲哚和1,2,3,4-四氢萘基。
“卤素”是指氟、氯、溴、碘,优选为氟和氯。
本发明的第二方面,还提供了一种芳基异喹啉并噁唑季铵盐类化合物的制备方法,该方法包括:
化合物R溶于溶剂中,加入酸HY,在一定温度下反应一段时间,去除溶剂,既得化合物P;
其中,
R11、R12、R13、R14、R15、R21、R22、R23、R24和Y-的定义与前述相同;
HY为Y-酸根阴离子所对应的酸,选自无机酸或有机酸,包括但不限于硝酸、硫酸、磷酸、甲磺酸、苯磺酸、醋酸、酒石酸、枸橼酸、马来酸、琥珀酸、柠檬酸、水杨酸、甘油酸、抗坏血酸、氢氟酸、氯化氢、氢溴酸或氢碘酸;
优选地,所述的溶剂包括但不限于甲苯、丙酮、二氯甲烷、1,2-二氯乙烷、四氢呋喃、乙腈、二甲苯、氯苯、二甲基亚砜、二甲基甲酰胺、二甲基乙酰胺、水中的一种或几种;所述的溶剂进一步优选为甲苯、丙酮、二氯甲烷、1,2-二氯乙烷、四氢呋喃、乙腈、水一种或几种;
优选地,所述的一定温度包括从零下80摄氏度至200摄氏度的任何温度;进一步优选为从0摄氏度到100摄氏度的任何温度;
所述的一段时间为0~48小时,优选为0.1~24小时;
所述去除溶剂的方法包括旋转蒸发、喷雾干燥、真空冷冻干燥和薄膜蒸发中的一种或多种。
本发明的第三方面是提供了一种药物组合物,它含有治疗有效量的选自根据本发明式 1所述的芳基异喹啉并噁唑季铵盐类化合物中的一种或多种作为活性成分,以及任选的药学上可接受的载体和/或赋形剂(例如,稀释剂等等)。
本发明的第四方面是提供了式1所述的芳基异喹啉并噁唑季铵盐类化合物和/或包含该化合物的药物组合物在制备预防或治疗肿瘤或癌症的药物中的用途,其中所述肿瘤或癌症优选为肺癌、结直肠癌、乳腺癌、肝癌、胃癌、宫颈癌、卵巢癌、胰腺癌、前列腺癌、甲状腺癌、骨髓瘤、淋巴瘤、白血病等。发明所述的化合物可以单独给药,或者与其他药学上可接受的治疗剂联合给药,特别是与其他预防或治疗肿瘤或癌症药物组合。所述治疗剂包括但不限于:氮芥、苯丁酸氮芥、环磷酰胺、异环磷酰胺、美法仑、塞替派、卡莫司汀、司莫司汀、白消安、顺铂、卡铂、草酸铂、丝裂霉素。
进一步优选地,还提供了式1所述的芳基异喹啉并噁唑季铵盐类化合物/或包含该化合物的药物组合物在制备预防或治疗血液肿瘤,如多发性骨髓瘤、淋巴瘤的药物中的用途。
有益效果
根据本发明的芳基异喹啉并噁唑季铵盐类化合物具有较好的体外抑制多发性骨髓瘤、淋巴瘤细胞生长的作用,活性均优于天然产物黄连素,并且在动物体内显著抑制多发性骨髓瘤细胞生长,不影响动物体重,具有开发成药的潜力。另外,该类化合物还对肺癌、结肠癌、乳腺癌、肝癌、前列腺癌细胞等具有一定的抑制活性,说明该类化合物具有广泛的抗肿瘤作用。
附图说明
图1为化合物P1抗多发性骨髓瘤细胞活性的对比图;
图2为化合物P1抗多发性骨髓瘤动物活性的对比图,其中,A为肿瘤体积的变化;B为肿瘤重量的差别;C为肿瘤大小的照片;D为动物体重的变化。
具体实施方式
下面结合具体实施例对本发明作进一步阐述,但不限制本发明。
制备实施例
本发明式1所述化合物的合成
原料R的制备参考文献Eur.J.Med.Chem.,2014,77:204-210的方法制得。样品数据由以下仪器测定:核磁共振氢谱(1H-NMR)用BrukerAvance III 300或400核磁共振仪;显色使用的精科WFH-203B三用紫外分析仪,波长为254nm和365nm。柱层析硅胶 (100-200目,300-400目)为青岛海洋化工厂生产;TLC硅胶板为烟台化工厂生产的 HSGF-254型薄层层析硅胶板,薄层层析使用的层析板厚度为0.2±0.03mm,预制备使用的薄层层析预制备板厚度为0.4-0.5mm;石油醚(沸程60-90℃),二氯甲烷,乙酸乙酯,甲醇均为分析纯,所用试剂如无特殊说明,均购自国药集团。
实施例1化合物P1的制备
将化合物R溶于丙酮中,向其中加入过量的氯化氢/无水乙醚,立即有大量的黄绿色固体析出,搅拌3h后,过滤,无水乙醚洗得化合物P1,收率为96%。1H NMR(300MHz, MeOD-d4)δ8.06(dd,J=9.0,1.3Hz,1H),7.91(dd,J=9.0,1.3Hz,1H),7.69(d,J=1.3Hz, 1H),7.27–7.17(m,2H),7.07(dd,J=8.5,1.5Hz,1H),6.61(d,J=3.2Hz,1H),6.11(d,J=1.4Hz,2H),5.29–5.17(m,2H),4.07(dd,J=2.4,1.4Hz,6H),3.08(d,J=1.3Hz,3H).13C NMR(126MHz,MeOD-d4)δ161.42,153.12,149.82,148.58,146.87,136.44,134.48,125.19,124.01,123.67,118.87,109.10,108.55,102.14,91.06,76.04,61.12,56.06,55.52.HRMS(ESI) 计算值C21H20O6N 382.1291[M+H]+,实测值382.1286。
实施例2化合物P2的制备
制备方法同实施例1,将化合物R1替换为化合物R2得化合物P2,收率为88%。1HNMR(400MHz,DMSO-d6)δ8.19(d,J=9.0Hz,1H),8.03(d,J=8.9Hz,1H),7.92(s,1H), 7.52–7.32(m,7H),7.29(s,2H),6.78(s,1H),5.34(s,2H),5.22(s,2H),4.05(s,3H),3.98(s,3H),3.88(s,3H),2.93(s,3H).13C NMR(125MHz,DMSO)δ161.07,152.95,149.70,146.15,137.12,136.55,134.49,128.93,128.46,128.36,126.11,124.97,124.76,122.35,119.07,114.07, 113.14,110.53,91.16,76.57,70.40,62.28,57.43,56.48,55.86.ESI-LR:474。
实施例3化合物P3的制备
制备方法同实施例1,将化合物R1替换为化合物R3得化合物P3,收率为92%。1HNMR(400MHz,CDCl3)δ7.80(d,J=8.9Hz,1H),7.74(d,J=9.0Hz,1H),7.54(s,1H),7.19 (s,2H),7.12(s,1H),6.12(s,1H),4.96(d,J=7.7Hz,1H),4.09–3.87(m,15H),2.97(s,3H)。
实施例4化合物P4的制备
制备方法同实施例1,将化合物R1替换为化合物R4得化合物P4,收率为99%。1HNMR(DMSO-d6,400MHz)δ8.54(1H,d,J=7.7Hz),8.32(2H,d,J=3.6Hz),8.24(2H,d, J=8.5Hz),8.16(1H,s),7.96(2H,d,J=7.7Hz),6.81(1H,d,J=6.4Hz),5.45(1H,dd,J=11.1,2.1Hz),5.30(1H,dd,11.1,6.4Hz),3.94(3H,s),3.88-3.91(1H,m),2.94(3H,s).HRMS(ESI): 计算值C20H18O4N+336.1230,实测值336.1239。
实施例5化合物P5的制备
制备方法同实施例1,将化合物R1替换为化合物R5得化合物P5,收率为94%。1HNMR(DMSO-d6,400MHz)δ8.50(d,J=8.0Hz,1H),8.29(d,J=3.9Hz,2H),8.04(s,1H), 7.41(d,J=2.0Hz,1H),7.37–7.33(m,1H),7.24(d,J=8.3Hz,1H),6.88(d,J=5.9Hz, 1H),5.41(d,J=11.1Hz,1H),5.31(dd,J=11.1,6.1Hz,1H),3.88(d,J=1.3Hz,6H), 3.80-3.84(m,1H),2.97(d,J=1.1Hz,3H).HRMS(ESI)m/z:计算值C20H20O4N+338.1387, 实测值338.1391。
实施例6化合物P6的制备
制备方法同实施例1,将化合物R1替换为化合物R6得化合物P6,收率为99%。1HNMR(DMSO-d6,500MHz)δ8.43(d,J=8.9Hz,1H),8.23(d,J=4.9Hz,2H),8.10(d,J=8.2 Hz,1H),7.94(s,1H),7.88(d,J=8.2Hz,1H),7.83(s,1H),7.70(d,J=7.0Hz,1H),7.55(s,1H),6.77(dd,J=6.0,1.8Hz,1H),5.36(dd,J=11.0,1.8Hz,1H),5.26(dd,11.0,6.0Hz,1H), 3.09-3.12(m,1H),2.94(s,3H).HRMS(ESI)m/z:计算值C18H16O3N+294.1125,实测值294.1122。
实施例7化合物P7的制备
制备方法同实施例1,将化合物R1替换为化合物R7得化合物P7,收率为91%。1HNMR(DMSO-d6,400MHz)δ8.54(d,J=8.2Hz,1H),8.32-8.33(m,2H),8.16(s,1H), 7.82-7.89(m,2H),7.69-7.77(m,1H),7.58-7.62(m,1H),6.79(dd,J=6.3,2.2Hz,1H),5.44 (dd,J=11.1,2.2Hz,1H),5.33(dd,J=11.1,6.3Hz,1H),4.21–3.94(m,1H),2.96(s,3H). HRMS(ESI)m/z:计算值C19H15O3F3N+362.0999,实测值362.1008。
实施例8化合物P8的制备
制备方法同实施例1,将化合物R1替换为化合物R8得化合物P8,收率为96%。1HNMR(DMSO-d6,400MHz)δ8.55(d,J=8.1Hz,1H),8.33(d,J=5.3Hz,2H),8.20(d,J=8.3 Hz,2H),8.16(s,1H),8.01(d,J=8.2Hz,2H),6.80(dd,J=6.3,2.2Hz,1H),5.48(dd,J=11.1,2.2Hz,1H),5.30(dd,J=11.1,6.5Hz,1H),3.44–3.35(m,1H),2.96(s,3H).HRMS(ESI) m/z:计算值C19H15O2N2 +303.1128,实测值303.1126。
实施例9化合物P9的制备
制备方法同实施例1,将化合物R1替换为化合物R9得化合物P9,收率为92%。1HNMR(DMSO-d6,400MHz)δ8.49(d,J=8.3Hz,1H),8.28(d,J=3.8Hz,2H),8.01(s,1H), 7.73(d,J=8.1Hz,2H),7.21(d,J=8.7Hz,2H),6.80(dd,J=5.5,1.8Hz,1H),5.41(dd, J=10.4,1.8Hz,1H),5.31(dd,10.4,5.5Hz,1H),4.16(q,J=6.8Hz,2H),4.09-4.12(m,1H),2.96 (s,3H),1.39(t,J=7.1Hz,3H).HRMS(ESI)m/z:计算值C20H20O3N[M]+322.1438,实测值322.1440。
实施例10化合物P10的制备
制备方法同实施例1,将化合物R1替换为化合物R10得化合物P10,收率为99%。1HNMR(DMSO-d6,400MHz)δ8.50(d,J=8.1Hz,1H),8.29(dd,J=4.0,1.3Hz,2H),8.09– 8.08(m,1H),7.15(d,J=2.0Hz,2H),6.95(dd,J=6.0,2.1Hz,1H),5.41(dd,J=11.0,2.0Hz,1H),5.36(dd,J=11.0,6.1Hz,1H),3.89(s,6H),3.77(s,3H),3.70-3.73(m,1H),3.00(s,3H).HRMS(ESI)m/z:计算值C21H22O5N+368.1492,实测值368.1487。
实施例11化合物P11的制备
制备方法同实施例1,将化合物R1替换为化合物R11得化合物P11,收率为97%。1HNMR(DMSO-d6,400MHz)δ8.50(d,J=8.2Hz,1H),8.30(d,J=3.7Hz,2H),8.05(s,1H), 7.75(d,J=8.1Hz,2H),7.61(d,J=8.2Hz,2H),6.82(dd,J=6.1,1.8Hz,1H),5.42(dd,J=11.1,1.8Hz,1H),5.30(dd,J=11.1,6.2Hz,1H),4.64(s,2H),4.20(s,1H),3.10-3.13(m,1H),2.93 (s,3H).HRMS(ESI)m/z:计算值C19H18O3N+308.1281,实测值308.1280。
实施例12化合物P12的制备
制备方法同实施例1,将化合物R1替换为化合物R12得化合物P12,收率为85%。1HNMR(DMSO-d6,400MHz)δ8.51(d,J=8.2Hz,1H),8.30(d,J=4.3Hz,2H),8.09(s,1H),7.64–7.58(m,1H),7.40–7.34(m,2H),7.24(s,1H),6.85(dd,J=6.2,2.1Hz,1H),5.42(dd,J=11.1,2.1Hz,1H),5.31(dd,11.1,6.2Hz,1H),3.88(s,3H),3.80-3.82(m,1H),2.95(s,3H). HRMS(ESI)m/z:计算值C19H18O3N+308.1281,实测值308.1290。
活性测试例
应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件如Sambrook等人,分子克隆:实验室手册(NewYork:Cold Spring Harbor Laboratory Press,1989)中所述的条件,或按照制造厂商所建议的条件。除非另外说明,否则百分比和份数按重量计算。
除非另行定义,文中所使用的所有专业与科学用语与本领域熟练人员所熟悉的意义相同。此外,任何与所记载内容相似或均等的方法及材料皆可应用于本发明方法中。文中所述的较佳实施方法与材料仅作示范之用。
测试例1对骨髓瘤细胞的活性影响
1.实验材料:
(1)细胞株:人多发性骨髓瘤细胞(ARP-1、OPM2、NCI-H929、RPMI-8226)细胞购自美国ATCC,本实验室传代保存。
(2)主要试剂:1640培养基(美国Gibco公司),胎牛血清(美国Gibco公司), CellCountingKit-8试剂盒(CCK8,日本株式会社同仁化学研究所)。
(3)主要仪器:二氧化碳培养箱(美国Thermo Forma公司),全自动酶标仪 (Bio-TEK,Elx800)。
2.实验方法:
(1)细胞培养
细胞培养于1640培养基(含10%胎牛血清,pH 7.2),培养基加2mmol/L谷氨酰胺,置于细胞培养箱中在37℃、5%CO2环境下培养。
(2)CCK8试剂盒测定各药物的细胞毒性
取人多发性骨髓瘤细胞(ARP-1、OPM2、NCI-H929、RPMI-8226细胞)的单细胞悬液,计数后调整细胞浓度至2×10^5个/mL。取96孔培养板每孔加入95μL上述细胞悬液,然后加不同浓度的用培养基配制的药物5μL,对照组加入相应体积的培养基,每组设置3 个平行孔。连续培养48h,培养结束前2h,每孔加入CCK8试剂10μL,于CO2孵箱中继续培养。2h后自动酶标仪检测450nm各孔OD值。计算细胞存活率与抑制率:细胞存活率(%)=(实验孔OD均值/对照孔OD均值)×100%。细胞抑制率(%)=100%-细胞存活率(%)。拟合函数求出抑制细胞生长达50%时药物浓度IC50。每组实验重复三次。
3.实验结果
表1化合物P1同黄连素的活性对比
实验结果说明,化合物P1对多发性骨髓瘤细胞有较好的抑制活性,且活性明显强于天然产物黄连素,见图1和表1。
表2部分化合物的抗多发性骨髓瘤的细胞活性
实验结果说明,该类化合物对多发性骨髓瘤细胞有较好的抑制活性,见表2。
测试例2针对多发性骨髓瘤的动物实验
1.实验材料
(1)细胞株:人多发性骨髓瘤细胞(NCI-H929细胞)(美国ATCC,本实验室传代保存),培养于1640培养基(含10%胎牛血清)。
(2)实验动物:雄性BALB/C裸鼠(6-8周,购自上海西普尔-必凯实验动物有限公司),置于SPF级环境中饲养(上海第十人民医院中心实验室动物房)。
2.实验方法
(1)细胞培养具体参见测试例1。
(2)动物实验
将含2×10^6个NCI-H929细胞的1640培养基注射到裸鼠左腋窝皮下,当瘤子长成并可测量时,随机分至对照组和给药组。给药组裸鼠每天腹腔注射10mg/kg,对照组裸鼠每天腹腔注射相同体积的溶剂(200μL,溶剂=15μL DMSO+185μL生理盐水)。每两天测量一次肿瘤大小(测量肿瘤的长和宽,肿瘤体积=4π/3×(宽/2)^2×(长/2))。给药20天后处死老鼠并取肿瘤拍照。
3.实验结果
实验结果说明,化合物P1有明显的动物体内抗多发性骨髓瘤活性,且对动物体重无显著影响,见图2。
测试例3针对人淋巴瘤细胞的杀伤活性
1.实验材料
人淋巴瘤细胞(OCI-LY1、OCI-LY8、NU-DUL-1、DB、U2932细胞)(美国ATCC,本实验室传代保存),培养于1640培养基(含10%胎牛血清)。其他同测试例1。
2.实验方法具体参见测试例1。
3.实验结果
表3化合物P1抗淋巴瘤细胞活性
OCI-LY1 | OCI-LY8 | NU-DUL-1 | DB | U2932 | |
化合物P1 | 6.29 | 0.46 | 1.96 | 3.88 | 4.09 |
黄连素 | 22.17 | 10.47 | 8.53 | 26.03 | N/A(>1000) |
实验结果说明,化合物P1有较显著的抗淋巴瘤细胞活性,且活性明显优于天然产物黄连素,见表3。
表4部分化合物的抗淋巴瘤细胞活性
实验结果说明,该类化合物具有较好的抗淋巴瘤细胞活性,见表4。
综上表明,作为黄连素类似物的芳基异喹啉并噁唑季铵盐化合物具有较好的体外抑制多发性骨髓瘤、淋巴瘤细胞生长的作用,活性均优于天然产物黄连素,并且在动物体内显著抑制多发性骨髓瘤细胞生长,不影响动物体重,具有开发成药的潜力。
测试例4针对其它实体瘤细胞的杀伤活性
1.实验材料
肿瘤细胞(A549,HCT16,MDA-MB-231,MHCC-97-H细胞)(美国ATCC,本实验室传代保存),培养于DMEM培养基(含10%胎牛血清)。DU145细胞美国ATCC,本实验室传代保存)培养于1640培养基(含10%胎牛血清),其他同测试例1。
2.实验方法具体参见测试例1。
3.实验结果
表5化合物P1针对其它肿瘤细胞的杀伤活性
实验结果说明,化合物P1对其它实体瘤细胞也有一定的杀伤活性,具有较广泛的抗肿瘤作用,见表5。
综上表明,芳基异喹啉并噁唑季铵盐类化合物具有广泛的抗肿瘤作用,且毒副作用小,具有开发成为抗肿瘤药物的潜力。
Claims (10)
1.下面式1所示的芳基异喹啉并噁唑季铵盐类化合物,或包含其作为活性成分以及任选的药学上可接受的载体和/或赋形剂的药物组合物在制备用于预防或治疗肿瘤或癌症的药物中的用途:
其中,
R11、R12、R13、R14、R15、R21、R22、R23、R24各自独立地选自氢、羟基、氨基、巯基、取代或未取代的C1-C6烷基、取代或未取代的C6-C12芳基、取代或未取代的C1-C6烷氧基、C1-C6烷氨基、C1-C6烷硫基、C1-C6烷氧基甲酰基、C6-C12芳醚基、C6-C12芳氨基、C6-C12芳硫基、硝基、C1-C6酰胺基或卤素;所述取代的取代基为羟基、氨基、巯基、卤素、C6-C12芳基或C1-C6烷基中的一个或多个;
或,R11、R12、R13、R14、R15中相邻的两个连接起来与相连的苯环上的碳原子形成一个5-7元环烷基或5-7元杂环基,其中,所述的5-7元杂环基包含选自O、S或N中1-3个的杂原子;
Y-为有机酸或无机酸的酸根阴离子。
2.根据权利要求1所述的用途,其中,Y-选自硝酸根离子、硫酸根、磷酸根、硫酸氢根离子、磷酸二氢根离子、甲磺酸根离子、苯磺酸根离子、醋酸根离子、酒石酸根离子、枸橼酸根离子、马来酸根离子、琥珀酸根离子、柠檬酸根离子、水杨酸根离子、甘油酸根离子、抗坏血酸根离子、氟离子、氯离子、溴离子或碘离子。
3.根据权利要求1所述的用途,其中,R11、R12、R13、R14、R15、R21、R22、R23、R24各自独立地选自氢、甲氧基、乙氧基、苄氧基、三氟甲氧基、羟基、羟基甲基、甲氧基甲酰基;或
R11、R12、R13、R14、R15中相邻的两个连接起来与相连的苯环上的碳原子形成一个二氧五环基。
4.根据权利要求3所述的用途,其中,R11、R12、R13、R14、R15中相邻的两个连接起来与相连的苯环上的碳原子形成一个1,3-二氧五环基。
6.根据权利要求1所述的用途,其中,所述药物组合物进一步包含其他药学上可接受的治疗剂。
7.根据权利要求6所述的用途,其中,所述其他药学上可接受的治疗剂是预防或治疗肿瘤或癌症的药物或其组合。
8.根据权利要求1所述的用途,其中,所述肿瘤或癌症选自肺癌、结直肠癌、乳腺癌、肝癌、胃癌、宫颈癌、卵巢癌、胰腺癌、前列腺癌、甲状腺癌中的一种或几种。
9.根据权利要求1所述的用途,其中,所述肿瘤为血液肿瘤。
10.根据权利要求9所述的用途,其中,所述血液肿瘤选自多发性骨髓瘤、淋巴瘤、白血病中的一种或几种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711384769.8A CN109942597B (zh) | 2017-12-20 | 2017-12-20 | 一类芳基异喹啉并噁唑季铵盐类化合物、其制备方法及用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711384769.8A CN109942597B (zh) | 2017-12-20 | 2017-12-20 | 一类芳基异喹啉并噁唑季铵盐类化合物、其制备方法及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109942597A CN109942597A (zh) | 2019-06-28 |
CN109942597B true CN109942597B (zh) | 2021-09-17 |
Family
ID=67005236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711384769.8A Expired - Fee Related CN109942597B (zh) | 2017-12-20 | 2017-12-20 | 一类芳基异喹啉并噁唑季铵盐类化合物、其制备方法及用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109942597B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107759614A (zh) * | 2016-08-16 | 2018-03-06 | 中国科学院上海药物研究所 | 一类噁唑并吡啶季铵盐类化合物、其制备方法及用途 |
-
2017
- 2017-12-20 CN CN201711384769.8A patent/CN109942597B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107759614A (zh) * | 2016-08-16 | 2018-03-06 | 中国科学院上海药物研究所 | 一类噁唑并吡啶季铵盐类化合物、其制备方法及用途 |
Non-Patent Citations (2)
Title |
---|
Anticancer medicines in development: assessment of bioactivity profiles within the National Cancer Institute anticancer screening data;David G. Covell,等;《Molecular Cancer Therapeutics》;20071231;第6卷(第8期);2261-2270 * |
Synthesis and Complete 1H and 13C Assignments of Thiazolo[3,2-a]quinolinium Derivatives;Osvaldo Cox,等;《Journal of Heterocyclic Chemistry》;19991231;第36卷(第4期);937-942 * |
Also Published As
Publication number | Publication date |
---|---|
CN109942597A (zh) | 2019-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105461738B (zh) | 一种雷帕霉素衍生物、其制备方法、其药物组合物及用途 | |
CN104797581B (zh) | 杂芳基炔烃化合物及其应用 | |
EP1710236B1 (en) | Derivatives of pyridine and quinoline | |
US9284315B2 (en) | Three-ring PI3K and/or mTOR inhibitor | |
AU2014292132B2 (en) | Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death | |
JP7304128B2 (ja) | 白金耐性の克服における使用のためのテキサフィリン-白金(iv)コンジュゲート及び組成物 | |
KR20040091083A (ko) | 이리노테칸 히드로클로라이드의 결정성 다형체 | |
EP2900667B1 (en) | Means and method for treating solid tumours | |
EP2432464B1 (en) | Nitrile derivatives and their pharmaceutical use and compositions | |
CN116917288A (zh) | 一种7,9-二氢嘌呤衍生物及其制药用途 | |
CN109942630B (zh) | 基于柳胺酚和紫檀芪的天然活性分子偶联化合物及其用途 | |
CN109553608A (zh) | 一类五元六元杂环化合物及其制备方法和治疗肿瘤的用途 | |
Liu et al. | Discovery of novel tacrine derivatives as potent antiproliferative agents with CDKs inhibitory property | |
CN109942597B (zh) | 一类芳基异喹啉并噁唑季铵盐类化合物、其制备方法及用途 | |
CN104230912A (zh) | 喹啉衍生物、其制备方法及其用途 | |
EP3369740B1 (en) | New cytidine derivative dimers and applications thereof | |
CN107474043A (zh) | 烟酸衍生物及其制备方法与用途 | |
CN109476649A (zh) | 五元杂环类化合物及其制备方法、药物组合物和用途 | |
WO2020042729A1 (zh) | 6-双硫取代-2'-脱氧鸟苷类化合物及其制备方法和应用 | |
CN108498518B (zh) | 七元环小檗碱类似物及其药物组合物在制备治疗多发性骨髓瘤的药物中的应用 | |
EP2896622B1 (en) | Pi3k and/or mtor inhibitor | |
EP1962850B1 (en) | Treatment of drug-resistant tumors | |
CN111569084B (zh) | 基于柳胺酚和紫檀芪的成环偶联分子dcz0801类化合物、其制备方法及用途 | |
KR20040062976A (ko) | 헥사사이클릭 화합물 | |
CN108864101B (zh) | 氘代sgx523 及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210917 |